Solventum Corp

Note 17 to the condensed consolidated financial statements provides an overview of Solventum’s business segments in addition to disclosures relating to Solventum’s segments. We manage our operations in four business segments. Our reportable segments are MedSurg, Dental Solutions, Health Information Systems, and Purification and Filtration. Our Chief Operating Decision Maker evaluates segment operating performance using net sales and business segment operating income.

Corporate and Unallocated

Certain items are maintained at the corporate level and not allocated to the segments ("Corporate and Unallocated"). Corporate and Unallocated includes amortization of acquired intangible assets, restructuring and related charges, and benefits or costs related to capitalized manufacturing variances. In addition, Corporate and Unallocated includes Spin-Off and separation related costs. Spin-Off and separation related costs include any costs incurred as part of our separation from 3M and costs to setup operations as a standalone company, including system implementations, manufacturing relocations, legal entity separations, certain equity awards granted as part of the Spin-Off, profit mark-ups on transition service arrangements with 3M and other one-time costs.

Corporate and Unallocated also includes sales and cost of sales related to our supply agreements with 3M and other supply agreements assumed by the Company at Spin-Off related to legacy 3M businesses. Because Corporate and Unallocated includes a variety of miscellaneous items, it is subject to fluctuation on a quarterly and annual basis.

Operating Business Segments

Information related to the Company’s segments is presented in the tables that follow with additional context in the corresponding narrative below the tables.

MedSurg (55.9% of consolidated sales for the three months ended March 31, 2025 )

First quarter 2025 results

Sales in MedSurg were up 3.4%:

•Organic growth was driven by strong broad-based volumes in Infection Prevention and Surgical Solutions, led by I.V. site management and hospital consumables.

•Advanced Wound Care volumes grew, driven by single-use negative pressure wound therapy consumables.

•Other includes lost sales from certain health care businesses in India retained by 3M in connection with the Spin-Off.

•Foreign currency translation negatively impacted sales by (1.6%).

Business segment operating income margin decreased when compared to the same period last year. The decrease was driven by higher costs to stand-up and operate our standalone structure after Spin-Off.

Dental Solutions (15.8% of consolidated sales for the three months ended March 31, 2025)

Sales in Dental Solutions were down (2.1)%:

•Organic growth in restorative and prevention solution products offset by declines in traditional orthodontic products.

•Other includes lost sales from certain health care businesses retained by 3M India in connection with the Spin-Off.

•Foreign currency translation negatively impacted sales by (1.9%).

Business segment operating income margin decreased when compared to the same period last year as a result of higher costs to stand-up and operate our standalone structure after Spin-Off and inventory-related charges that are not expected to continue in 2025.

Health Information Systems (15.9% of consolidated sales for the three months ended March 31, 2025)

Sales in Health Information Systems were up 3.6%:

•Organic growth was driven by continued adoption of our 3MTM 360 Encompass TM.

•Foreign currency translation negatively impacted sales by (0.3%).

Business segment operating income margin increased when compared to the same period last year driven by temporary savings from the Company's Solventum Way restructuring program, partially offset by higher compensation costs.

Purification and Filtration (11.7% of consolidated sales for the three months ended March 31, 2025)

Sales in Purification and Filtration were down (0.9)%:

•Organic growth was driven by continued strength in bioprocessing filtration and industrial filtration, which benefited from added production capacity, partially offset by declines in membrane OEM products.

•Other includes lost sales from certain health care businesses in India retained by 3M in connection with the Spin-Off.

•Foreign currency translation negatively impacted sales by (2.0)%.

Business segment operating income margin decreased due to a negative impact from higher compensation-related costs and costs to stand-up and operate our standalone structure after Spin-Off, partially offset by benefits from sales mix.